Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Regulatory News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 137.50
Bid: 135.00
Ask: 140.00
Change: -2.50 (-1.79%)
Spread: 5.00 (3.704%)
Open: 140.00
High: 137.50
Low: 133.00
Prev. Close: 140.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Faron receives grant from Business Finland

11 May 2020 10:00

RNS Number : 4705M
Faron Pharmaceuticals Oy
11 May 2020
 

Faron Pharmaceuticals Oy

("Faron" or the "Company")

 

Faron receives €800,000 grant from Business Finland as part of Cancer IO, Finland's leading Personalized Health Program

- Grant will enable state-of-the-art characterization of immunological responses in MATINS trial- Clevegen to be studied in experimental combinations with anti-cancer molecules from other consortium members

Company announcement, 11 May 2020 at 12.00 PM (EET)Inside information

 

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that it has joined a Finnish consortium, Cancer IO, and received an €800,000 grant from Business Finland to conduct detailed, state-of-the-art characterization of the immunological responses seen in cancer patients in the Company's MATINS trial.

 

The ongoing phase I/II MATINS clinical trial is investigating the tolerability, safety and efficacy of Clevegen, Faron's wholly-owned novel precision cancer immunotherapy targeting Clever-1 positive tumour associated macrophages (TAM), in selected metastatic or inoperable solid tumours.

 

As part of the Business Finland backed initiative, Faron will also study Clevegen in combination with other anti-cancer molecules, in experimental settings together with other consortium members.

 

Cancer IO is a new cancer immunotherapy-focused €10 million top-level collaborative research and innovation project within Business Finland's Personalized Health Program. Coordinated by the University of Helsinki, it integrates immuno-oncology (IO) activities at the universities of Helsinki and Turku, three Finnish university hospitals and one central hospital, eight Finnish SMEs, Finnish cancer patient organizations and nine of the largest IO-investing pharmaceutical companies operating in Finland. Cancer IO has been established to drive the creation of a Finnish IO ecosystem and national IO growth strategy, aiming to provide wealth and well-being through disruptive Nordic IO innovations and better care. Faron's participation in this significant national immuno-oncology effort will include sharing clinical development expertise and samples from ongoing trials, and providing Clevegen for consortium experiments.

 

Dr. Markku Jalkanen, Faron's CEO, said: "We are very pleased to join this leading initiative, which will deepen our understanding of Clevegen's effects during the MATINS trial, enable us to better characterize and understand the immune responses of patients receiving novel treatments, test different therapies in combination with Clevegen in a variety of laboratories and experimental settings, as well as possibly find new leads to take further into development."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

For more information please contact:

 

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com 

 

Panmure Gordon (UK) Limited, Nomad and Broker

Emma Earl, Freddy Crossley (Corporate Finance)

James Stearns (Corporate Broking)

Phone: +44 207 886 2500

 

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen, Jussi Majamaa

Phone: +358 (0)40 555 4727

 

Consilium Strategic Communications

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

 

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine. Faron is based in Turku, Finland. Further information is available at www.faron.com 

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should", "expect", "hope", "seek", ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In particular, the early data from initial patients in the MATINS trial may not be replicated in larger patient numbers and the outcome of clinical trials may not be favourable or clinical trials over and above those currently planned may be required before the Company is able to apply for marketing approval for a product. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully licence its programmes within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward looking statements. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAPSFFFFEEEA
Date   Source Headline
28th Mar 20247:00 amRNSIssue of Warrants to IPF Funding Update
26th Mar 202410:00 amRNSFaron´s Annual Report 2023
18th Mar 20247:00 amRNSAdditional Positive Data from Phase 1 of BEXMAB
14th Mar 20247:00 amRNSFaron to Host BEXMAB Webcast
13th Mar 20242:00 pmRNSNotice of Annual General Meeting 2024
13th Mar 20247:00 amRNSFinancial Statement January 1 to December 31 2023
4th Mar 20247:00 amRNSBinding commitments for convertible loans
28th Feb 20244:00 pmRNSReplacement - Update to 2024 Financial Calendar
27th Feb 20246:00 pmRNSUpdate to Faron’s Financial Calendar for 2024
21st Feb 20242:00 pmRNSContinued Negotiations Regarding Events of Default
19th Feb 202410:30 amRNSEvents of Default
31st Jan 20247:00 amRNSFurther re: Exercise of options
25th Jan 20247:00 amRNSBEXMAB Insights into Patient Profiles
19th Jan 20241:00 pmRNSExercise of options - Issue of equity
9th Jan 20247:00 amRNSFirst Patient Dosed in Ph 2 of the BEXMAB Trial
3rd Jan 20247:00 amRNSPresentation at J.P. Morgan Healthcare Conference
22nd Dec 20237:00 amRNSFaron’s Financial Calendar for 2024
11th Dec 20237:00 amRNSPhase 1 BEXMAB data presented at ASH
7th Dec 20237:00 amRNSMATINS Trial in Cell Reports Medicine
4th Dec 20237:00 amRNSGrant of options
6th Nov 20238:13 amRNSFaron Initiates Phase 2 Part of BEXMAB Study
6th Nov 20237:00 amRNSFaron Initiates Phase 2 Part of BEXMAB Study
2nd Nov 20231:00 pmRNSFaron to present data from BEXMAB study at ASH
27th Oct 20231:00 pmRNSManager's transactions
27th Oct 20237:15 amRNSExercise of options
27th Oct 20237:00 amRNSResults of Placing
26th Oct 20234:30 pmRNSProposed Issue and Placing
11th Oct 20237:00 amRNSFaron Announces Positive BEXMAB Study Update
3rd Oct 20237:00 amRNSFaron to host webcast on new BEXMAB study data
22nd Sep 20234:00 pmRNSBoard Changes
22nd Sep 202311:00 amRNSResults of EGM
21st Sep 20237:00 amRNSFaron Appoints Interim Chief Medical Officer
8th Sep 20237:00 amRNSChange in the Board of Directors
6th Sep 20237:00 amRNSFaron to Present at H.C. Wainwright Conference
1st Sep 202310:00 amRNSNotice of EGM
31st Aug 20232:00 pmRNSExercise of options
29th Aug 20237:01 amRNSFaron 2023 Half-Year Financial Results
29th Aug 20237:00 amRNSFDA Orphan Drug Designation for Bexmarilimab
4th Aug 20237:00 amRNSNotice of Half-Year Financial Results
2nd Aug 20237:00 amRNSFaron to Participate at Canaccord Conference
25th Jul 20237:00 amRNSGrant of Options
19th Jul 20237:01 amRNSFaron to Hold BEXMAB Study Conference Call
19th Jul 20237:00 amRNSBEXMAB study update
30th Jun 20234:52 pmRNSHolding(s) in Company
29th Jun 20237:00 amRNSAnnouncement of Placing
12th Jun 20237:00 amRNSExercise of options
9th Jun 20238:00 amRNSNew biomarker data from BEXMAB study at EHA2023
5th Jun 20237:00 amRNSBoard Member to Assume Transactional Advisor Role
24th Apr 20237:00 amRNSBexmarilimab Efficacy and Safety in MATINS Trial
19th Apr 20237:00 amRNSBexmarilimab KOL Event

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.